4 Results for "

ATX-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "ATX-IN-2" in MCE Product Catalog:

Cat. No.: HY-174267S
CAS No.: 3076224-81-9
ATX-IN-2 (Compound 25) is an orally active and potent ATX inhibitor with an IC50 value of 3.27 nM. ATX-IN-2 reduces lysophosphatidic acid (LPA) secretion. ATX-IN-2 is promising for research of ATX-mediated diseases, such as inflammation, pulmonary fibrosis .
loading...
    loading...
Cat. No.: HY-145344
CAS No.: 1354805-08-5
Purity:  99.68%
Research Areas:  

Cancer

ONO-8430506 is an orally bioavailable and potent autotaxin (ATX)/ENPP2 inhibitor with the IC90 of 100 nM for ATX activity in mouse plasma [2] .
loading...
    loading...
Cat. No.: HY-126233
CAS No.: 1689554-51-5
Research Areas:  

Others

PAT-347 is an inhibitor of autotaxin (ATX, ENPP-2) . PAT-347 binds only to the hydrophobic channel of ATX, without occupying its hydrophobic pocket and catalytic site . PAT-347 blocks the binding of lysophosphatidylcholine (LPC) to the catalytic site of ATX [2].
loading...
    loading...
Cat. No.: HY-119601
CAS No.: 313685-55-1
Research Areas:  

Cancer

GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC50=31.42 nM, Ki=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus .
loading...
    loading...